1

1

1

Breakthrough innovation in the fight against pancreatic cancer

Breakthrough innovation in the fight against pancreatic cancer

CC&C is a Medtech start-up. We rely on the latest discoveries in the field of oncology and in particular physical oncology and mechanobiology, to develop a treatment against pancreatic cancer.

Learn more about our technology…

In 2016, we published our Proof of Concept in PlosOne. This experiment validated the action of mechanical stress on a grafted tumor in mice. This is the first time in the world that such a result is obtained on live animals, and not in cell cultures.

Read our article …

Today, our goal is to experimentally validate the action of our device on human pancreatic cancer grafted in mouse pancreas. To do this, we have initiated two partnerships, one in the United States with the prestigious Stanford University, the other in a European consortium around the Bichat Faculty of Medicine in Paris, a world leader in Digestive Oncology.

Learn more about our Proof of Efficacy…

Our medium-term strategy: to finish research within two years and move on to a human prototype, with the goal of a first human experiment in 2022.

Why such a rapid development?

What is Cell Constraint & Cancer ?

of research

raised in 2018

before placing on the market

subscribe to our capital increase

Invest in a breakthrough innovation, unique and patented.

Development faster than a drug.

Latest news from CC&C

NanoStress: we answered the FET-Open call for projects

The FET-Open call of the European Commission finances disruptive innovation research projects capable of « changing the world ». We did not need it any less, so we submitted today a nomination file within the NanoStress consortium, in order to obtain the Proof of...
Lire la suite

Results for the first quarter 2018

- WITH THE SUPPORT OF INSERM, GET EUROPEAN FUNDS - LAST FUNDRAISE BEFORE CHANGING OUR FUNDING MODEL     The FET-Open call for projects, which is part of the Horizon 2020 program for research initiated by the European Commission, selects its laureates for...
Lire la suite

In vivo: Proof of Efficacy

The principles The possibility of therapeutic use, of course, opens up enormous opportunities. The method fits into the current conception of carcinogenesis: impossibility of thinking the cancerous transformation without integrating the interaction Extra Cellular...
Lire la suite

9 + 8 =

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles